Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. by Ruszniewski, P, Ish-Shalom, S, Wymenga, M, O'Toole, D, Arnold, R, Tomassetti, P, Bax, N, Caplin, M, Eriksson, B, Glaser, B, Ducreux, M, Lombard-Bohas, C, de Herder, W, Delle Fave, G, Reed, N, Seitz, J, Van Cutsem, E, Grossman, A, Rougier, P, Schmidt, W, Wiedenmann, B